NDAINTRAVENOUSSOLUTION
Approved
Sep 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RUBY-FILL is a rubidium Rb 82 diagnostic radiopharmaceutical administered intravenously for cardiac imaging. It is used in myocardial perfusion imaging to assess coronary artery disease and cardiac viability. The product leverages the rapid kinetics of rubidium-82, a generator-produced positron-emitting isotope.
Peak
Product is in peak commercial phase; team likely stable in size with focus on market penetration in cardiac imaging centers.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RUBY-FILL offers careers in diagnostic imaging commercialization, with roles concentrated in sales, medical affairs, and operations. Working on this product provides experience in nuclear medicine and PET imaging markets, a specialized but stable therapeutic area.
Diagnostic Sales RepresentativeMedical Science Liaison
Worked on RUBY-FILL at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.